Researchers said while the risk is low, the rising use of GLP-1s in patients with and without Type 2 diabetes warrants special attention to medication safety
GLP-1 promotes the disassembly of F-actin, improving cell glucose sensitivity and insulin secretion following sustained glucotoxicity 7
Overall loss of muscle mass ranged from 32-45% and none of the 10 experimental treatment groups experienced any significant changes in muscle mass when administered treatment
TNBC tissue has significant ECM deposition and severe fibrosis, which causes tumour vascular compression and lowers perfusion, which impairs drug delivery (41)
Gastroenterology 12 (8), e00386
So, whos most at risk, and what can you do if you fall into one of these groups